Health Economics›Diffuse large B-cell lymphoma›Relapsed or refractory further lines of therapy

Relapsed or refractory further lines of therapy

Diffuse large B-cell lymphoma · 48 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 9 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Blinatumomab monotherapy Variant #05	—	R 4 812 257	56d	—	~7.7 mo	~1	~R 4 812 257 PFS proxy · indirect	2
Ofatumumab monotherapy Variant #03	—	R 512 332	28d	~8.1 mo	—	~6	~R 3 073 989 PFS proxy · indirect	4
Bendamustine and Rituximab (BR) and Polatuzumab vedotin Variant #01	—	R 279 851	21d	—	12.4 mo	6	R 917 267 PFS proxy	1
ViPOR Variant #01	—	R 237 624	21d	—	—	~6	~R 1 117 031 indirect	—
Glofitamab monotherapy Variant #01	—	R 193 746	21d	—	—	~11	~R 1 485 388 indirect	—
Everolimus and Rituximab Variant #01	—	R 161 653	28d	—	—	~5	~R 338 711 indirect	—
Lenalidomide and Rituximab (R2) Variant #08	—	R 134 502	28d	—	8.5 mo	11	R 396 684 PFS proxy	1
Obinutuzumab monotherapy Variant #06	—	R 95 395	21d	—	—	~7	~R 238 487 indirect	—
Ibrutinib monotherapy Variant #01	—	R 81 964	28d	~22.1 mo	~30.3 mo	~2	~R 163 929 PFS proxy · indirect	2
Brentuximab vedotin monotherapy Variant #01	—	R 56 829	21d	~25.6 mo	—	~17	~R 966 097 PFS proxy · indirect	2
TTR Variant #01	—	R 45 512	21d	—	—	~6	~R 273 071 indirect	—
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	—	9.5 mo	8	R 270 994 PFS proxy	1
R-BL Variant #01	—	R 33 396	28d	—	—	~6	~R 200 374 indirect	—
R-GemOx Variant #01	—	R 31 779	15d	3.8 mo	12.9 mo	8	R 230 735 PFS proxy	2
Gemcitabine and Rituximab Variant #01	—	R 30 921	28d	—	9.5 mo	6	R 185 526 PFS proxy	1
R-CVEP Variant #01 Partial	—	R 26 658	28d	—	—	~6	~R 159 950 indirect	—
R-INO Variant #01 Partial	—	R 25 905	28d	—	9.5 mo	8	R 207 238 PFS proxy	1
Panobinostat and Rituximab Variant #01 Partial	—	R 25 905	21d	—	—	~2	~R 51 809 indirect	—
GVD Variant #01	—	R 20 259	21d	—	—	~6	~R 121 555 indirect	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~2	~R 36 719 PFS proxy · indirect	15
ICE Variant #05	—	R 12 735	—	—	~13.9 mo	~4	~R 50 942 PFS proxy · indirect	—
Etoposide, Ifosfamide, Methotrexate Variant #01	—	R 12 589	21d	—	—	~2	~R 25 177 indirect	—
DICE Variant #01	—	R 12 529	28d	—	—	~2	~R 25 057 indirect	—
Ifosfamide monotherapy Variant #05	—	R 8 704	21d	~4.0 mo	~8.4 mo	~8	~R 69 635 PFS proxy · indirect	2
Bendamustine monotherapy Variant #01	—	R 7 084	—	~16.5 mo	—	~8	~R 56 672 PFS proxy · indirect	2
DICEP Variant #01	—	R 6 506	—	—	—	~1	~R 6 506 indirect	—
Lenalidomide and Tafasitamab Variant #01 Partial	—	R 5 445	28d	—	—	~12	~R 65 340 indirect	—
Mitoxantrone monotherapy Variant #01	—	R 5 139	21d	—	—	~2	~R 10 278 indirect	—
GDP Variant #01	—	R 4 133	21d	—	—	~3	~R 12 398 indirect	—
ESHAP Variant #01	—	R 3 886	21d	—	—	~8	~R 31 091 indirect	—
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	—	—	~24	~R 52 272 PFS proxy · indirect	1
EPOCH Variant #01	—	R 2 138	21d	—	—	~8	~R 17 104 indirect	—
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	~5.2 mo	—	~7	~R 11 705 PFS proxy · indirect	1
CEPP(B) Variant #01 Partial	—	R 1 574	30d	—	—	~2	~R 3 148 indirect	—
Oxaliplatin monotherapy Variant #01	—	R 1 265	21d	—	—	~6	~R 7 590 indirect	—
Etoposide monotherapy Variant #01	—	R 1 231	28d	—	—	~6	~R 7 386 indirect	—
Vinorelbine monotherapy Variant #01	—	R 458	21d	~4.0 mo	~9.4 mo	~12	~R 5 490 PFS proxy · indirect	26
Ibritumomab tiuxetan protocol Variant #18 Partial	—	—	8d	~36.5 mo	—	~1	—	1
Rituximab monotherapy Variant #09 Partial	—	—	28d	~5.2 mo	—	~1	—	3
Loncastuximab tesirine monotherapy Variant #01 Partial	—	—	21d	—	—	~16	—	—
Axicabtagene ciloleucel monotherapy Variant #01 Partial	—	—	—	—	—	1	—	1
Temsirolimus monotherapy Variant #02 Partial	—	—	28d	~4.8 mo	~23.5 mo	~2	—	2
Tisagenlecleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Panobinostat monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—
Epcoritamab monotherapy Variant #01 Partial	—	—	28d	—	—	~6	—	—
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Selinexor monotherapy Variant #01 Partial	—	—	7d	~2.8 mo	—	~2	—	1
Pixantrone monotherapy Variant #01 Partial	—	—	28d	—	—	~6	—	—

48 of 48 regimens shown